Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, França MC Jr, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceição I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M; NEURO-TTRansform Investigators.
JAMA. 2023 Oct 17;330(15):1448-1458. doi: 10.1001/jama.2023.18688.
Renal amyloidosis: an update on diagnosis and pathogenesis.
Gupta N, Kaur H, Wajid S.
Protoplasma. 2020 Sep;257(5):1259-1276. doi: 10.1007/s00709-020-01513-0. Epub 2020 May 24.
Renal amyloidosis: a new time for a complete diagnosis.
Feitosa VA, Neves PDMM, Jorge LB, Noronha IL, Onuchic LF.
Braz J Med Biol Res. 2022 Oct 3;55:e12284. doi: 10.1590/1414-431X2022e12284. eCollection 2022.
Hereditary renal amyloidosis with a variant lysozyme p.Trp82Arg in a Chinese family: case report and literature review.
Li Z, Xu H, Liu D, Li D, Liu G, Wang SX.
BMC Nephrol. 2019 Aug 8;20(1):310. doi: 10.1186/s12882-019-1496-6.
Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study.
Dang J, Ferlicot S, Misrahi M, Mussini C, Kounis I, Rémy P, Samuel D, Planté-Bordeneuve V, Adams D, Funalot B, Snanoudj R, Damy T, Moktefi A, Audard V, Zaidan M.
Nephrol Dial Transplant. 2023 Aug 31;38(9):2019-2030. doi: 10.1093/ndt/gfad006.
2024 Update on Classification, Etiology, and Typing of Renal Amyloidosis: A Review.
Leung N, Nasr SH.
Am J Kidney Dis. 2024 Sep;84(3):361-373. doi: 10.1053/j.ajkd.2024.01.530. Epub 2024 Mar 19.
Amyloidosis.
Bustamante JG, Zaidi SRH.
2023 Jul 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.
Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G.
J Neurol. 2021 Jun;268(6):2109-2122. doi: 10.1007/s00415-019-09688-0. Epub 2020 Jan 6.
Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience.
Ferraro PM, D'Ambrosio V, Di Paolantonio A, Guglielmino V, Calabresi P, Sabatelli M, Luigetti M.
Brain Sci. 2021 Jul 24;11(8):980. doi: 10.3390/brainsci11080980.
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ.
J Clin Pharmacol. 2020 Jan;60(1):37-49. doi: 10.1002/jcph.1480. Epub 2019 Jul 19.
